Page last updated: 2024-12-06

ginkgolide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ginkgolide B is a terpene trilactone found in the leaves and seeds of the ginkgo tree (Ginkgo biloba). It has been shown to have a variety of pharmacological activities, including anti-inflammatory, anti-allergic, and neuroprotective effects. Ginkgolide B is a potent inhibitor of platelet-activating factor (PAF), a lipid mediator involved in inflammation, allergy, and thrombosis. The compound is currently being investigated for its potential therapeutic use in a variety of conditions, including asthma, Alzheimer's disease, and stroke.'

FloraRankFlora DefinitionFamilyFamily Definition
Ginkgogenus[no description available]Ginkgoaceae[no description available]
Ginkgo bilobaspeciesThe only specie of the genus Ginkgo, family Ginkgoacea. It is the source of extracts of medicinal interest, especially Egb 761. Ginkgo may refer to the genus or species.[MeSH]Ginkgoaceae[no description available]
Ginkgogenus[no description available]Ginkgoaceae[no description available]
Ginkgo bilobaspeciesThe only specie of the genus Ginkgo, family Ginkgoacea. It is the source of extracts of medicinal interest, especially Egb 761. Ginkgo may refer to the genus or species.[MeSH]Ginkgoaceae[no description available]
Ginkgogenus[no description available]Ginkgoaceae[no description available]
Ginkgo bilobaspeciesThe only specie of the genus Ginkgo, family Ginkgoacea. It is the source of extracts of medicinal interest, especially Egb 761. Ginkgo may refer to the genus or species.[MeSH]Ginkgoaceae[no description available]

Cross-References

ID SourceID
PubMed CID65243
CHEMBL ID266625
SCHEMBL ID14279903
MeSH IDM0133140
PubMed CID102004390
MeSH IDM0133140
PubMed CID6324617
CHEMBL ID514432
SCHEMBL ID12714280
MeSH IDM0133140

Synonyms (47)

Synonym
PDSP2_000724
NCGC00025245-01
PDSP1_000734
nsc110257
nsc-110257
gingko lactone
ginkolide b
c20h24o10
99796-69-7
L000993
CHEMBL266625
AKOS015895882
SCHEMBL14279903
tert-butyl-trihydroxy-methyl-[?]trione
SR-01000597598-1
SR-01000597598-3
sr-01000597598
7-deoxyginkgolide c
1-hydroxy-(1beta)-ginkgolide a
BCP25992
8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
AS-56165
ginklide b
15291-77-7
ginkgolide b ,
AKOS037514661
ginkgolide b from ginkgo biloba leaves, >=90% (hplc)
smr000544403
MLS001216216
gingkolide b
bdbm50251276
ginkgolide-b
DB06744
CHEMBL514432 ,
HMS2864N19
ginkgolide b from ginkgo biloba leaves
AKOS025311549
MLS006011991
SCHEMBL12714280
Q-100180
ginkgolide b, analytical standard
SQOJOAFXDQDRGF-MMQTXUMRSA-N
ginkgolide b,(s)
Q27095719
G-170
((1r,3r,6r,7s,8s,10r,11r,12r,13s,16s,17r)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0^{1,11}.0^{3,7}.0^{7,11}.0^{13,17}]nonadecane-5,15,18-trione.
18 - potency of gingko biloba

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cyclosporin (CsA) is a potent immunosuppressive drug whose main side-effect is nephrotoxicity."( Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist.
Aupetit, B; Baghos, W; Bagnis, C; Braquet, P; Deray, G; Dubois, M; Jacobs, C; Jacquiaud, C; Pirotzky, E, 1996
)
0.29
" Finally we show that Abeta is less toxic to N2a neuroblastoma cells when the peptide is previously incubated with the flavonoid fraction or EGb 761 during the fibril formation period."( Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation.
Christen, Y; Garneau, P; Longpré, F; Ramassamy, C, 2006
)
0.33

Pharmacokinetics

The paper is aimed to investigate the effect of cyclosporine A (CyA) on the pharmacokinetics of ginkgolide B (GB) in rats. The aim is to look for the mechanism of the changes in pharmacokinetic behaviors of GB.

ExcerptReferenceRelevance
" 4, 12 and 36 mg/kg GB emulsion, the pharmacokinetic parameters from a two compartment model analysis of plasma samples were AUC(0-tau) (microg x min/ml): 53."( Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats.
Chen, WD; Liang, Y; Liu, XD; Lu, T; Wang, GJ; Xie, L, 2007
)
0.34
" The method has been successfully applied to a pharmacokinetic study of Ginkgo biloba extract in rats after intravenous administration."( Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats.
Ding, C; Ge, Q; Xie, J; Zhi, X; Zhou, Z, 2008
)
0.35
"The paper is aimed to investigate the effect of cyclosporine A (CyA) on the pharmacokinetics of ginkgolide B (GB) in rats, and to look for the mechanism of the changes in pharmacokinetic behaviors of GB."( [Effect of cyclosporine A on the pharmacokinetics of ginkgolide B in rats].
Chen, XJ; Gao, ZD; Han, DE; Li, N; Sun, W; Wang, L, 2009
)
0.35
"0 mg/kg ginkgolide B, parameters of pharmacokinetics of ginkgolide B were: Tmax were all (0."( [Study on the pharmacokinetics of ginkgolide B for injection in rats].
Jiao, HY; Suo, QL; Zhang, XT, 2012
)
0.38
" The validated method was successfully applied to a pharmacokinetic study of PGB and GB in rats after intravenous administration."( Validated LC-MS-MS method for the determination of prodrug of ginkgolide B in rat plasma and brain: application to pharmacokinetic study.
Hui, A; Pan, J; Wu, Z; Yuan, Y; Zhou, A, 2013
)
0.39
"05), but the Cmax values of BB, GA, GB and GC were significantly decreased (p<0."( Effects of food and gender on the pharmacokinetics of ginkgolides A, B, C and bilobalide in rats after oral dosing with ginkgo terpene lactones extract.
Cai, BC; Chai, C; Di, LQ; Huang, P; Li, JS; Li, W; Qian, XC; Zhang, L, 2014
)
0.4
" To investigate the main pharmacokinetic characteristics of three different GB formulations in beagle dogs, a simple, specific and sensitive LC-MS/MS method was established and validated."( Pharmacokinetics of Ginkgolide B after Oral Administration of Three Different Ginkgolide B Formulations in Beagle Dogs.
Ding, G; Geng, T; Guo, Q; Huang, W; Li, Y; Si, H; Sun, X; Wang, Q; Xiao, W; Zhao, J, 2015
)
0.42
" For the first time, we showed that the fed dogs had significantly increased area under the concentration-time curve and peak concentration relative to the fasted dogs based on the data from both the prototype form and total lactones of ginkgolide A (GA) and ginkgolide B (GB)."( The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs.
Aa, J; Aa, L; Fei, F; Liu, C; Tan, Z; Wang, G, 2018
)
0.48
" The currently available GB injections have a short half-life and are lethal when injected rapidly."( Pharmacokinetics of ginkgolide B-lyophilized nanoparticles after intravenous injection in rats using liquid chromatography-tandem mass spectrometry.
Li, J; Liu, Q; Ma, L; Peng, J; Shi, J; Xiong, Y; Xu, S; Zhang, H; Zhao, Y; Zhu, L, 2023
)
0.91
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

The platelet activating factor receptor antagonist ginkgolide B (GB) and the carotenoid antioxidant astaxanthin (ASX) interact with antihistamines cetirizine dihydrochloride (CTZ) and azelastine (AZE) to potentiate their ability to downregulate immune activation.

ExcerptReferenceRelevance
" Here we hypothesize that the platelet-activating factor receptor antagonist ginkgolide B (GB) in combination with the antioxidant carotenoid astaxanthin (ASX) suppresses T cell activation comparably to two commonly-used antihistamines: cetirizine dihydrochloride (CTZ) and azelastine (AZE)."( In vitro effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in peripheral blood mononuclear cells from asthmatic subjects.
Abal, AT; Abul, HT; Haines, DD; Mahmoud, FF; Onadeko, BO; Wise, JA, 2004
)
0.32
" It is hypothesized that the platelet activating factor receptor antagonist ginkgolide B (GB) and the carotenoid antioxidant astaxanthin (ASX) interact with antihistamines cetirizine dihydrochloride (CTZ) and azelastine (AZE) to potentiate their ability to downregulate potentially pathological immune activation."( In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin.
Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012
)
0.38

Bioavailability

Ginkgolide B alleviates endothelial dysfunction by reducing oxidative stress and elevating NO bioavailability and H2S production in diabetic rats.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The bioavailability of ginkgolides in these extracts was assessed in rabbits in comparison with a commercially available standardized 24/6 extract."( The bioavailability of ginkgolides in Ginkgo biloba extracts.
Li, CL; Wong, YY, 1997
)
0.3
"The bioavailability of ginkgolides A, B and bilobalide was studied in rats after single oral administration of 30, 55 and 100 mg/kg Ginkgo extract EGb 761."( Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS.
Biber, A; Koch, E, 1999
)
0.3
" With respect to the relevance of biopharmaceutical quality of herbal medicinal products, two different Ginkgo biloba brands (test product: Ginkgo biloba capsules; reference product: Ginkgold) were analysed for dissolution rates and bioavailability of the most relevant active ingredients."( Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations.
Biber, A; Blume, HH; Kressmann, S; Müller, WE; Schug, B; Wonnemann, M, 2002
)
0.31
"To study the pharmacokinetics and bioavailability of ginkgolides sustained-release tablet and conventional tablet in Beagle dogs."( [Pharmacokinetics of ginkgolides sustained-release tablet].
Guo, Q; Jin, M; Lv, Y; Sun, X; Xiao, W; Zhang, X, 2011
)
0.37
" The relative bioavailability of ginkgolides A was 88."( [Pharmacokinetics of ginkgolides sustained-release tablet].
Guo, Q; Jin, M; Lv, Y; Sun, X; Xiao, W; Zhang, X, 2011
)
0.37
" To investigate the effects of food and gender on the bioavailability of BB, GA, GB and GC after oral administration of GTL extract, a rapid UPLC-MS/MS method was developed and validated."( Effects of food and gender on the pharmacokinetics of ginkgolides A, B, C and bilobalide in rats after oral dosing with ginkgo terpene lactones extract.
Cai, BC; Chai, C; Di, LQ; Huang, P; Li, JS; Li, W; Qian, XC; Zhang, L, 2014
)
0.4
"001), reduced NO bioavailability and H2S production (P<0."( Ginkgolide B increases hydrogen sulfide and protects against endothelial dysfunction in diabetic rats.
Chen, QY; Li, W; Lu, XH; Wang, GG; Zhao, X, 2015
)
0.42
"Ginkgolide B alleviates endothelial dysfunction by reducing oxidative stress and elevating NO bioavailability and H2S production in diabetic rats."( Ginkgolide B increases hydrogen sulfide and protects against endothelial dysfunction in diabetic rats.
Chen, QY; Li, W; Lu, XH; Wang, GG; Zhao, X, 2015
)
0.42
"To investigate the pharmacokinetic characteristics and absolute bioavailability of ginkgolide A (GA), ginkgolide B (GB) and bilobalide (BB) in rats."( [Absolute bioavailability of ginkgolide compounds in rats].
Geng, T; Si, HH; Sun, XP; Xue, J; Zhao, J, 2015
)
0.42
" To address the poor bioavailability of ginkgo diterpene lactones, ginkgo diterpene lactone meglumine injection (GDLI) was formulated and is commercially available."( Pharmacokinetics and tissue distribution of ginkgolide A, ginkgolide B, and ginkgolide K after intravenous infusion of ginkgo diterpene lactones in a rat model.
Aa, J; Fei, F; Geng, J; Geng, T; Huang, W; Li, Y; Ouyang, B; Peng, Y; Wang, G; Wang, J; Wang, P; Wang, S; Wang, Z; Xiao, W, 2016
)
0.43
" However, few studies have evaluated the bioavailability of ginkgolides and the effects of food on it after oral administration of ginkgolides."( The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs.
Aa, J; Aa, L; Fei, F; Liu, C; Tan, Z; Wang, G, 2018
)
0.48
" Nanocrystals (NCs) can increase dissolution velocities and saturation solubility, improving oral bioavailability and brain uptake."( Highly stabilized nanocrystals delivering Ginkgolide B in protecting against the Parkinson's disease.
Chen, T; Chen, X; Li, Y; Liu, W; Liu, Y; Luo, J; Wang, Q; Xiong, S; Zhang, Z; Zhao, Y, 2020
)
0.56
" Despite its promising therapeutic properties, GB has poor bioavailability following oral administration and cannot readily achieve sufficient exposure in treated patients, limiting its clinical application for the treatment of PD."( Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson's Disease.
Chen, T; Chen, X; Liu, P; Liu, W; Liu, Y; Shi, X; Tan, H; Wang, Q; Xiong, S; Zhao, Y, 2020
)
0.56
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Ginkgolide B nanosuspension lyophilized powder orodispersible film (GB-NS-LP-ODF) To further elucidate the cellular effects of ginkgalide B.

ExcerptRelevanceReference
" The effect was most pronounced 5 min after dosing the inhibitor and detectable over a period of 30 min."( Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Hofmann, B; Kertscher, HP; Ostermann, G; Till, U, 1990
)
0.28
" In explanted rat hypothalami maintained viable in vitro, PAF stimulated immunoreactive CRH secretion in a bell-shaped dose-response fashion."( The alkyl-ether phospholipid platelet-activating factor is a stimulator of the hypothalamic-pituitary-adrenal axis in the rat.
Bernardini, R; Brucke, T; Calogero, AE; Chrousos, GP; Ehrlich, YH; Gold, PW, 1989
)
0.28
" All antagonists produced a shift to the right in the dose-response curve to Paf (0."( Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation.
Bittner, C; Lambrecht, G; Parnham, MJ, 1989
)
0.28
" PAF injected into the peritoneal cavity induced a bell-shaped dose-response curve of EB extravasation in both strains of mouse."( Differential sensitivity of mouse strains to platelet activating factor-induced vasopermeability and mortality: effect of antagonists.
Jancar, S; Russo, M; Vásquez-Bravo, YL, 1993
)
0.29
" Eighty Wistar rats were divided into a sham-operated group, two control groups, and four study groups, according to the dosage and route of BN 52021 administration."( Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model.
Alsina, J; Bordalba, JR; Carrera, M; Griño, JM; Martinez-Castelao, A; Moliner, R; Seron, D; Torras, J; Valles, J, 1993
)
0.29
" Each rat was first measured mean pulmonary arterial pressure (mPAP), mean systemic arterial pressure (mSAP) and the ratio of the weight of right ventricle to that of left ventricle plus septum [RV/(LV + S)], than two main pulmonary artery rings were isolated to exposed to PDBu(a specific activator of PKC) to observe the time-response curve and the dose-response curve in response to 500 nmol/L PDBu and 10-11,000 nmol/L PDBu respectively to evaluate the function of protein kinase C signal channel."( [The effect of ginkgo biloba on hypoxic pulmonary hypertension and the role of protein kinase C].
Xu, Y; Yang, H; Zhang, Z, 2000
)
0.31
" Corresponding dose-response relationships are close to single-site binding isotherms."( Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators.
Chatterjee, SS; Kondratskaya, EL; Krishtal, OA, 2003
)
0.32
" To further elucidate the cellular effects of ginkgolide B, we examined the dose-response effect of ginkgolide B on ethanol-induced toxicity in human Hep G2 cells."( Dosage effects of ginkgolide B on ethanol-induced cell death in human hepatoma G2 cells.
Chan, WH; Hsuuw, YD, 2007
)
0.34
"To determine the optimal dosage and mechanism of Ginkgolide B (BN52021) on severe acute pancreatitis (SAP) of rats."( Mechanism and dose-effect of Ginkgolide B on severe acute pancreatitis of rats.
Di, Y; Ji, RL; Xia, SH; Xu, W, 2011
)
0.37
"By iv injection, 5 mg/kg of BN52021 is the optimal dosage for SAP rats."( Mechanism and dose-effect of Ginkgolide B on severe acute pancreatitis of rats.
Di, Y; Ji, RL; Xia, SH; Xu, W, 2011
)
0.37
" Results demonstrate improved activity of antihistamines by 2 phytochemicals, suggesting dosing strategies for animal trials of ASX- or GB-augmented formulations for seasonal allergic rhinitis and asthma."( In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin.
Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012
)
0.38
" GB reached a steady state by day 6 with once-daily dosing at 40 mg."( A sensitive LC-MS/MS method to determine ginkgolide B in human plasma and urine: application in a pharmacokinetics and excretion study of healthy Chinese subjects.
Huang, H; Huang, X; Jin, X; Li, F; Li, J; Liu, J; Rong, G; Shen, C; Song, S; Wu, M, 2020
)
0.56
"To prepare a new dosage form that can improve the drug loading of the film--ginkgolide B nanosuspension lyophilized powder orodispersible film(GB-NS-LP-ODF) and to evaluate its quality."( [Preparation and quality evaluation of orodispersible film containing ginkgolide B novel nanosuspension lyophilized powder].
Bao-de, S; Bo, D; Hai-Long, Y; Jing, W; Jun-Jun, Z; Ting, Z; Ya-Ning, Z, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886
EWS/FLI fusion proteinHomo sapiens (human)Potency14.88360.001310.157742.8575AID1259252; AID1259253; AID1259255
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
Guanine nucleotide-binding protein GHomo sapiens (human)Potency11.22021.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-glucuronidaseHomo sapiens (human)IC50 (µMol)6.63000.02003.08337.4000AID1656436
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.74000.00430.75777.8000AID167654
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)Ki0.88000.00040.33863.2500AID157887
Glycine receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)2.37150.02700.81873.8000AID281247; AID281248; AID281250
Glycine receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)3.84051.99532.94413.9811AID281249
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)IC50 (µMol)1.70000.00040.15553.8000AID281250
Platelet-activating factor receptorHomo sapiens (human)IC50 (µMol)0.12800.00030.63183.7000AID154446
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)1.70000.00040.13343.8000AID281250
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.18000.18000.18000.1800AID154450
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorHomo sapiens (human)Binding affinity3.41000.60003.41006.2200AID154444; AID154445
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
carbohydrate metabolic processBeta-glucuronidaseHomo sapiens (human)
glycosaminoglycan catabolic processBeta-glucuronidaseHomo sapiens (human)
heparan sulfate proteoglycan catabolic processBeta-glucuronidaseHomo sapiens (human)
chondroitin sulfate catabolic processBeta-glucuronidaseHomo sapiens (human)
hyaluronan catabolic processBeta-glucuronidaseHomo sapiens (human)
glucuronoside catabolic processBeta-glucuronidaseHomo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-2Homo sapiens (human)
monoatomic ion transmembrane transportGlycine receptor subunit alpha-2Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-2Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-2Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-2Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-2Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-2Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-2Homo sapiens (human)
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
beta-glucuronidase activityBeta-glucuronidaseHomo sapiens (human)
signaling receptor bindingBeta-glucuronidaseHomo sapiens (human)
protein domain specific bindingBeta-glucuronidaseHomo sapiens (human)
carbohydrate bindingBeta-glucuronidaseHomo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-2Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-2Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
glycine-gated chloride ion channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
metal ion bindingGlycine receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-2Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular regionBeta-glucuronidaseHomo sapiens (human)
extracellular spaceBeta-glucuronidaseHomo sapiens (human)
membraneBeta-glucuronidaseHomo sapiens (human)
azurophil granule lumenBeta-glucuronidaseHomo sapiens (human)
lysosomal lumenBeta-glucuronidaseHomo sapiens (human)
intracellular membrane-bounded organelleBeta-glucuronidaseHomo sapiens (human)
extracellular exosomeBeta-glucuronidaseHomo sapiens (human)
ficolin-1-rich granule lumenBeta-glucuronidaseHomo sapiens (human)
extracellular spaceBeta-glucuronidaseHomo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-2Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-2Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-2Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-2Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-2Homo sapiens (human)
synapseGlycine receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-2Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-2Homo sapiens (human)
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (117)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1707196Inhibition of [3H]PAF-acether binding to PAFR in rabbit platelet plasma membranes incubated for 1 hr2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1386710Antagonist activity at rabbit PAF receptor assessed as inhibition of PAF-induced platelet aggregation incubated for 5 mins followed by PAF addition2018Journal of natural products, 09-28, Volume: 81, Issue:9
Tetrahydrobenzofuran-6(2 H)-one Neolignans from Ocotea heterochroma: Their Platelet Activating Factor (PAF) Antagonistic Activity and in Silico Insights into the PAF Receptor Binding Mode.
AID479192Antiinflammatory activity in rat PMNC assessed as inhibition of platelet activating factor-induced beta-glucuronidase release preincubated for 15 mins at 37 degC2010Journal of natural products, May-28, Volume: 73, Issue:5
Neolignans and glycosides from the stem bark of Illicium difengpi.
AID1056520Antiinflammatory activity in rat polymorphonuclear leukocytes assessed as inhibition of PAF-induced release of glucuronidase at 10 uM2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID1056516Cytotoxicity against human Bel7402 cells at 10 uM after 96 hrs by MTT assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID1082435Inhibition of fruit-infesting behavior of Cydia pomonella (codling moth) neonates infested in apple fruit plugs assessed as feeding deterrence index at 0.1 mg/mL2011Journal of agricultural and food chemistry, Oct-26, Volume: 59, Issue:20
Effects of Ginkgo biloba constituents on fruit-infesting behavior of codling moth (Cydia pomonella) in apples.
AID167654Inhibition of PAF-induced rabbit platelet aggregation1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
AID636749Antiinflammatory activity in rat polymorphonuclear leukocytes assessed as inhibition of platelet-activating factor-induced glucuronidase release at 10 uM preincubated for 15 mins before challenge by spectrophotometry2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Homosecoiridoids from the flower buds of Lonicera japonica.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID281247Activity at human alpha-1GlyR expressed in HEK293 cells by FMP assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID1056517Cytotoxicity against human MCF7 cells at 10 uM after 96 hrs by MTT assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID281249Activity at human alpha-2GlyR expressed in HEK293 cells by FMP assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID281250Activity at human alpha-1GlyR expressed in HEK293 cells assessed as inhibition of 300 uM glycine-induced current by whole-cell patch clamp experiment2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056514Cytotoxicity against human HCT8 cells at 10 uM after 96 hrs by MTT assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1056518Cytotoxicity against human BGC823 cells at 10 uM after 96 hrs by MTT assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID358945Antiinflammatory activity against cytochalasin-activated human PMNC assessed as inhibition of platelet activating factor-induced elastase release by p-nitroanilide formation assay2002Journal of natural products, Jan, Volume: 65, Issue:1
A neutrophil multitarget functional bioassay to detect anti-inflammatory natural products.
AID1707177Inhibition of PAFR in New Zealand rabbit platelets assessed as reduction in PAF-induced platelet aggregation measured within 5 mins by aggregometry analysis2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1056519Cytotoxicity against human A549 cells at 10 uM after 96 hrs by MTT assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID1082437Inhibition of fruit-infesting behavior of Cydia pomonella (codling moth) neonates infested in apple fruit plugs assessed as feeding deterrence index at 10 mg/mL2011Journal of agricultural and food chemistry, Oct-26, Volume: 59, Issue:20
Effects of Ginkgo biloba constituents on fruit-infesting behavior of codling moth (Cydia pomonella) in apples.
AID401364Displacement of [3H]PAF from rabbit PAF receptor by liquid scintillation counting1998Journal of natural products, Jun-26, Volume: 61, Issue:6
Magnone A and B, novel anti-PAF tetrahydrofuran lignans from the flower buds of Magnolia fargesii.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID492013Antiinflammatory activity in rat PMNC assessed as inhibition of platelet-activating factor-induced beta-glucuronidase release2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Thiodiketopiperazines produced by the endophytic fungus Epicoccum nigrum.
AID154444Compound was evaluated for anti-platelet activating factor potency1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
A 3D-QSAR study on ginkgolides and their analogues with comparative molecular field analysis.
AID281248Activity at human alpha-1-beta-GlyR expressed in HEK293 cells by FMP assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID154450Inhibition of [3H]PAF binding to rabbit platelet membrane1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
AID355029Inhibition of PAF-induced exocytosis in neutrophil by spectrophotometer1996Journal of natural products, Jun, Volume: 59, Issue:6
Isolation of two new antiinflammatory biflavanoids from Sarcophyte piriei.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID443495Antiplatelet activity in rabbit platelets assessed as inhibition of adenosin 5'-diphosphate-induced platelet aggregation2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID157887Displacement of [3H]-WEB 2086 from Platelet activating factor receptor (guinea pig) transgenic mouse muscle membrane2003Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4
Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.
AID443494Antiplatelet activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID154445Binding affinity against platelet activating factor1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
A 3D-QSAR study on ginkgolides and their analogues with comparative molecular field analysis.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1707178Antiproliferative activity against human OVCA429 cells incubated for 72 hrs by MTT assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID426073Antiplatelet activity in rabbit platelets assessed as inhibition of PAF-induced platelet aggregation treated 5 mins before PAF challenge2009Journal of natural products, Jul, Volume: 72, Issue:7
Macrophyllin-type bicyclo[3.2.1]octanoid neolignans from the leaves of Pleurothyrium cinereum.
AID1056515Cytotoxicity against human Ketr3 cells at 10 uM after 96 hrs by MTT assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID385377Antiinflammatory activity in rat polymorphonuclear leukocytes assessed as inhibition of platelet activating factor-induced release of beta-glucuronidase at 10 uM after 15 mins2008Journal of natural products, May, Volume: 71, Issue:5
Glycosides from the bark of Adina polycephala.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1707199Suppression of ZEB1 protein level in human T-24 cells incubated for 24 hrs by Western blot analysis2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID426152Antiplatelet activity in rabbit platelets assessed as inhibition of PAF-induced platelet aggregation treated 5 mins before PAF challenge relative to cinerin C2009Journal of natural products, Jul, Volume: 72, Issue:7
Macrophyllin-type bicyclo[3.2.1]octanoid neolignans from the leaves of Pleurothyrium cinereum.
AID443493Antiplatelet activity in rabbit platelets assessed as inhibition of platelet activating factor-induced platelet aggregation2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
AID600670Antiinflammatory activity in rat Polymorphonuclear leukocytes assessed as inhibition of platelet-activating factor-induced beta-glucuronidase release at 10 uM2011Journal of natural products, May-27, Volume: 74, Issue:5
Dimeric prenylated C6-C3 compounds from the stem bark of Illicium oligandrum.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID384981Antiinflammatory activity against rat polymorphonuclear leucocytes assessed as inhibition of platelet activating factor-induced beta-glucuronidase release2008Journal of natural products, May, Volume: 71, Issue:5
Lignan glycosides from Neoalsomitra integrifoliola.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID154446Compound was evaluated for anti-platelet activating factor potency1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
A 3D-QSAR study on ginkgolides and their analogues with comparative molecular field analysis.
AID1656436Inhibition of beta-glucuronidase (unknown origin)2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID1082436Inhibition of fruit-infesting behavior of Cydia pomonella (codling moth) neonates infested in apple fruit plugs assessed as feeding deterrence index at 1 mg/mL2011Journal of agricultural and food chemistry, Oct-26, Volume: 59, Issue:20
Effects of Ginkgo biloba constituents on fruit-infesting behavior of codling moth (Cydia pomonella) in apples.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1056513Antiviral activity against HIV1 infected in human 293T cells expressing VSV-G assessed as inhibition of viral p24 production at 10 uM after 48 hrs by ELISA2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (833)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990156 (18.73)18.7374
1990's311 (37.33)18.2507
2000's173 (20.77)29.6817
2010's142 (17.05)24.3611
2020's51 (6.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.41 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (34.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials20 (2.37%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews32 (3.80%)6.00%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.12%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other790 (93.71%)84.16%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]